Ipsogen can now offer DNAVision’s microarray profiling services at the level of quality of quantitative PCR, the industry gold standardIpsogen, a molecular diagnostic company based in France and Connecticut, has signed an agreement with DNAVision, a provider of pharmacogenomic services in Europe. Ipsogen gains the capability to offer its portfolio of breast cancer profiling tests to institutions and patients in a Clia/ISO17025 certified environment.
